Trial · NCT04770753
Results by group92
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 92
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Double-Blind Period: Percentage of Participants Who Achieved Hemoglobin (Hb) Response From Week 12 Through Week 24 Compared With Baseline | Mitapivat | 42.3 | Percentage of participants | ||
| Double-Blind Period: Percentage of Participants Who Achieved Hemoglobin (Hb) Response From Week 12 Through Week 24 Compared With Baseline | Placebo | 1.6 | Percentage of participants | ||
| Double-Blind Period: Change From Baseline in Average Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue Subscale Score From Week 12 Through Week 24 | Mitapivat | 4.85 | Standard Error 0.732 | score on a scale | |
| Double-Blind Period: Change From Baseline in Average Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue Subscale Score From Week 12 Through Week 24 | Placebo | 1.46 | Standard Error 0.955 | score on a scale | |
| Double-Blind Period: Change From Baseline in Average Hb Concentration From Week 12 Through Week 24 | Mitapivat | 8.57 | Standard Error 0.666 | Gram per Liter (g/L) | |
| Double-Blind Period: Change From Baseline in Average Hb Concentration From Week 12 Through Week 24 | Placebo | -1.06 | Standard Error 0.867 | Gram per Liter (g/L) | |
| Double-Blind Period: Percentage of Participants Who Achieved Hb 1.5+ Response From Week 12 Through Week 24 Compared With Baseline | Mitapivat | 24.6 | Percentage of participants | ||
| Double-Blind Period: Percentage of Participants Who Achieved Hb 1.5+ Response From Week 12 Through Week 24 Compared With Baseline | Placebo | 0 | Percentage of participants | ||
| Double-Blind Period: Change From Baseline in Indirect Bilirubin at Week 24 | Mitapivat | -10.65 | Standard Error 1.047 | Micromole per Liter (umol/L) | |
| Double-Blind Period: Change From Baseline in Indirect Bilirubin at Week 24 | Placebo | -0.03 | Standard Error 1.403 | Micromole per Liter (umol/L) | |
| Double-Blind Period: Change From Baseline in Lactate Dehydrogenase (LDH) at Week 24 | Mitapivat | -30.07 | Standard Error 7.131 | Units per Liter (U/L) | |
| Double-Blind Period: Change From Baseline in Lactate Dehydrogenase (LDH) at Week 24 | Placebo | -5.79 | Standard Error 9.440 | Units per Liter (U/L) | |
| Double-Blind Period: Change From Baseline in Haptoglobin at Week 24 | Mitapivat | -0.002 | Standard Error 0.0145 | Gram per Liter (g/L) | |
| Double-Blind Period: Change From Baseline in Haptoglobin at Week 24 | Placebo | 0.017 | Standard Error 0.0199 | Gram per Liter (g/L) | |
| Double-Blind Period: Change From Baseline in Reticulocytes at Week 24 | Mitapivat | -32.11 | Standard Error 10.600 | 10^9 cells per liter (10^9 cells/L) | |
| Double-Blind Period: Change From Baseline in Reticulocytes at Week 24 | Placebo | -14.74 | Standard Error 14.932 | 10^9 cells per liter (10^9 cells/L) | |
| Double-Blind Period: Change From Baseline in Erythropoietin at Week 24 | Mitapivat | 19.21 | Standard Error 37.773 | International units per Liter (IU/L) | |
| Double-Blind Period: Change From Baseline in Erythropoietin at Week 24 | Placebo | 115.71 | Standard Error 49.413 | International units per Liter (IU/L) | |
| Double-Blind Period: Percentage of Participants Who Achieved Patient Global Impression of Severity (PGIS)- Fatigue Response at Weeks 12, 16, 20, and 24 | Mitapivat | At Week 12 | 65.4 | percentage of participants | |
| Double-Blind Period: Percentage of Participants Who Achieved Patient Global Impression of Severity (PGIS)- Fatigue Response at Weeks 12, 16, 20, and 24 | Placebo | At Week 12 | 46.9 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04770753/results